Delving into the Latest Updates on Korean Red Cross with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Congenital Disorders

Immune System Diseases

Immunoglobulin

Non-recombinant coagulation factor

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Hemic and Lymphatic Diseases	2
Immune System Diseases	1

Top 5 Drug Type	Count

Immunoglobulin	1
Non-recombinant coagulation factor	1

Author: Wai‐Chiu Tsoi ; Magdy El Ekiaby ; Roberta Fachini ; Masahiro Satake ; Kate Tettmar ; Ai Leen Ang ; Syria Laperche ; Snežna Levičnik Stezinar ; Susan L. Stramer ; Piotr Grabarczyk ; Philip Kiely ; Sheila F. O'Brien ; Magdalena Łętowska ; Peter Flanagan ; Marion Vermeulen ; So‐Yong Kwon ; Jean‐Pierre Allain ; Margaret Fearon ; Patricia Santos Prado Scuracchio ; Katy Davison ; Eun Young Oh ; Aneta Kopacz ; Maria Piron ; Fiona Boland ; Michael Schmidt ; Patricia. E. Hewitt ; Giles Delages ; Erhard Seifried ; Clive R. Seed ; Sally Lam ; Polona Nograšek ; Miquel Lozano ; Louise Pomeroy ; Padraig Williams ; Patricia Carminato ; Sylvie Gross ; Sze Sze Chua ; Niamh O'Flaherty ; Richard Charlewood ; Silvano Wendel ; Lisa M. Jarvis ; Pierre Gallian ; Veronica C. Hoad ; Rikizo Taira ; Marta Bes ; Silvia Sauleda ; Juraj Petrik ; Jun Nyun Kim ; Keiji Matsubayashi

01 Mar 2018·Annals of clinical and laboratory science

Cryopreservation of Genotyped ABO Subgroup RBCs for Quality Assurance of ABO Grouping Reagents.

Article

Author: Song, Sungwook ; Kim, Sinyoung ; Kim, Hyun Ok

BACKGROUNDQuality assurance of newly developed or manufactured blood grouping reagents with reagent red blood cells (RBCs) is crucial in the process of product approval by governmental agency. However, RBCs with rare blood group are not easily available in the fresh state. We investigated the feasibility of cryopreserved and genotyped ABO subgroup RBC reagents for quality assurance purpose.METHODSWe obtained RBCs from 10 volunteers with ABO subgroup phenotypes. The ABO genotypes and alleles were analyzed by the sequencing of ABO exon 6 and 7. Using the 40% wt/vol high-glycerol method, RBC units were cryopreserved as reagent RBCs into separate cryovials at -80°C. The potency titrations were performed before and after cryopreservation for 6 months and 2 years to evaluate the stability of ABO antigens.RESULTSABO genotypes of cryopreserved RBCs were cis-AB01/O01 (n=2), cis-AB01/B101 (n=1), Aw10/B101 (n=2), A201/A201 (n=1), A205/B101 (n=1), A102/B112 (n=1), and A101/B306 (n=1). These ABO subgroup alleles are exclusively present in East-Asian population except for the known ABO*A201 allele. The potency titers of cryopreserved RBCs were not significantly different between pre-freezing and post-freezing.CONCLUSIONSThe national performance evaluation of ABO blood grouping reagents could be performed with cryopreserved and genotyped reagent RBCs.

01 Jan 2016·Medical Principles and PracticeQ4 · MEDICINE

Combined Use of Malaria Antigen and Antibody Enzyme-Linked Immunosorbent Assay for Blood Screening of Plasmodium vivax in the Republic of Korea

Q4 · MEDICINE

ArticleOA

Author: Deok Ja Oh ; Jin Woo Jang ; Chae Seung Lim ; Ju Yeon Kim ; Jeeyong Kim

Objective: To evaluate the clinical sensitivity and specificity of the newly developed Genedia malaria antigen enzyme-linked immunosorbent assay (ELISA) test and to evaluate the diagnostic efficiency of the combined use of the Genedia malaria antigen and antibody ELISA tests to detect Plasmodium vivax in blood samples. Materials and Methods: In all, 1,070 samples were analyzed: 300 P. vivax-infected patients, 41 samples from posttreatment patients upon follow-up and 729 healthy volunteers. The Genedia malaria antigen ELISA test and the Genedia malaria antibody ELISA 2.0 test were evaluated and compared to polymerase chain reaction and microscopy. Results: The Genedia malaria antigen ELISA test had a clinical sensitivity of 94.7% (284/300) and a clinical specificity of 99.3% (724/729). The Genedia malaria antibody ELISA 2.0 test had a clinical sensitivity of 94.0% (282/300) and a clinical specificity of 98.4% (717/729). The Genedia malaria antigen ELISA test was able to detect 13 confirmed P. vivax cases without antibodies against P. vivax, whereas the Genedia malaria antibody ELISA 2.0 test detected 11 confirmed P. vivax cases nonreactive to the Genedia malaria antigen ELISA test, and 25 cases from 41 follow-up samples nonreactive in the Genedia malaria antigen ELISA test. The combined Genedia malaria antigen and antibody ELISA 2.0 tests had a clinical sensitivity of 98.3% (295/300) and a clinical specificity of 97.9% (714/729). Conclusion: The combination of antigen and antibody ELISAs improved the diagnostic sensitivity in P. vivax-confirmed cases in the Republic of Korea.

100 Deals associated with Korean Red Cross

Login to view more data

100 Translational Medicine associated with Korean Red Cross

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Rho(D) Immune Globulin Intravenous (Human)(Cangene Corp)	Transfusion Reaction More	Approved
Human Blood Coagulation Factor VIII (Korean Red Cross)	Von Willebrand Diseases More	Approved